# Function of Yogurt Fermented with the Lactococcus lactis 11/19-B1 Strain in Improving the Lipid Profile and Intestinal Microbiome in Hemodialysis Patients

**Authors:** Yoshiki Suzuki, Ken Ishioka, Taichi Nakamura, Nozomu Miyazaki, Shigeru Marubashi, Tatsuo Suzutani

PMC · DOI: 10.3390/nu17111931 · Nutrients · 2025-06-04

## TL;DR

A yogurt made with Lactococcus lactis 11/19-B1 may help improve cholesterol and gut health in dialysis patients.

## Contribution

This study evaluates the impact of a specific yogurt strain on lipid profiles and gut microbiome in hemodialysis patients.

## Key findings

- Yogurt consumption reduced LDL cholesterol in hemodialysis patients.
- Indoxylsulfate levels decreased in most participants with initially high concentrations.
- Stool characteristics improved, but no significant change in TMAO levels was observed.

## Abstract

Background/Objectives: The number of chronic kidney disease (CKD) patients is increasing in Japan, and this population is at high risk of death from cardiovascular and cerebrovascular diseases. Therefore, prevention of arteriosclerosis as a common underlying cause of these diseases is required. In this study, we examined whether 11/19-B1 yogurt, which has been proven to reduce serum low-density lipoprotein (LDL) levels, can decrease the serum levels of indoxylsulfate and trimethylamine-N-oxide (TMAO), which are produced by intestinal microbiota and known to cause arteriosclerosis, through improving dysbiosis in hemodialysis patients. Methods: Nineteen dialysis patients consumed 50 g of 11/19-B1 yogurt daily for 8 weeks, and changes in serum lipid profile and uremic toxin levels, intestinal microbiome, as well as the frequency of bowel movement and stool characteristics were observed. Results: The results demonstrated that an intake of yogurt decreased serum LDL 99.3 to 88.5 (p = 0.049) and indoxylsulfate in seven of nine subjects with previously high concentrations, and improved stool characteristics as estimated by the Bristle stool score, although decreased HDL and no beneficial effect on serum TMAO was observed. Conclusions: These results may suggest that the ingestion of 11/19-B1 yogurt provides a preventative effect against the progression of atherosclerosis and renal dysfunction.

## Linked entities

- **Chemicals:** indoxylsulfate (PubChem CID 10258), trimethylamine-N-oxide (PubChem CID 1145)
- **Diseases:** chronic kidney disease (MONDO:0005300), atherosclerosis (MONDO:0005311)

## Full-text entities

- **Diseases:** CKD (MESH:D051436), arteriosclerosis (MESH:D001161), death (MESH:D003643), uremic (MESH:D006463), cardiovascular and cerebrovascular diseases (MESH:D002318), atherosclerosis (MESH:D050197), renal dysfunction (MESH:D007674)
- **Chemicals:** N (MESH:D009584), i (MESH:D007455), Lipid (MESH:D008055), TMAO (-), -oxide (MESH:D010087), trimethylamine (MESH:C023336), indoxylsulfate (MESH:D007200)
- **Species:** Lactococcus lactis (species) [taxon 1358], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12157043/full.md

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12157043/full.md

## References

45 references — full list in the complete paper: https://tomesphere.com/paper/PMC12157043/full.md

---
Source: https://tomesphere.com/paper/PMC12157043